Major Depressive Disorder in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2029

List of Contents

List of Tables

List of Figures

1 Major Depressive Disorder: Executive Summary

1.1 MDD therapeutics market will grow to $9.5 billion by 2029

1.2 Key players will struggle to maintain their competitive position

1.3 Better efficacy and rapid onset of action are the most pressing unmet needs in the MDD market

1.4 Novel late-stage pipeline drugs will be a key driver of growth

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Disease staging systems

3.3 Prognosis

3.4 Quality of life

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 Forecast methodology

4.4.1 Sources used

4.4.2 Sources not used

4.4.3 Forecast assumptions and methods

4.4.4 Forecast assumptions and methods: 12-month total prevalence of MDD

4.4.5 Forecast assumptions and methods: 12-month total prevalence of MDD by severity

4.5 Epidemiological forecast for MDD (2019–29)

4.5.1 12-month total prevalent cases of MDD

4.5.2 Age-specific 12-month total prevalence of MDD

4.5.3 Sex-specific 12-month total prevalent cases of MDD

4.5.4 12-month total prevalent cases of MDD by severity for ages <18 years

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Rapid onset of action

7.3 New therapies with better efficacy

7.4 Improved safety profiles

7.5 Management of patient outcome expectations

8 R&D Strategies

8.1 Overview

8.1.1 Novel MOAs

8.1.2 Development of adjunctive therapies

8.1.3 Digital therapeutics

8.1.4 Personalized treatments/biomarkers

8.2 Clinical trials design

8.2.1 Study design

8.2.2 Endpoints

8.2.3 Placebo response rate

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

10.2.1 Monotherapies

10.2.2 Adjunctive therapies

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

12.5 Canada

12.5.1 Forecast

12.5.2 Key events

12.5.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs interviewed for this report.

13.4.1 KOLs

13.5 Primary research – prescriber survey

13.6 About the authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologist

13.6.5 Vice President of Disease Intelligence and Epidemiology

13.6.6 Global Head of Pharma Research, Analysis and Competitive Intelligence

About GlobalData

Contact Us

Table 1: MDD: Key metrics in the 8MM

Table 2: DSM-V criteria of major depressive episode

Table 3: ICD-10 criteria of major depressive episode

Table 4: Subtypes of major depressive episode

Table 5: Risk factors and comorbidities for MDD

Table 6: Treatment guidelines for MDD

Table 7: MDD market – global drivers and barriers, 2019–29

Table 8: Key events impacting sales for MDD in the US, 2019–29

Table 9: MDD market – drivers and barriers in the US, 2019–29

Table 10: Key events impacting sales for MDD in the 5EU, 2019–29

Table 11: MDD market – drivers and barriers in the 5EU, 2019–29

Table 12: Key events impacting sales for MDD in Japan, 2019–29

Table 13: MDD market – drivers and barriers in Japan, 2019–29

Table 14: Key events impacting sales for MDD in Canada, 2019–29

Table 15: MDD market – drivers and barriers in Canada, 2019–29

Table 16: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for MDD in 2019 and 2029

Figure 2: Analysis of the company portfolio gap in MDD during the forecast period

Figure 3: Overview of targets of antidepressant action on noradrenergic and serotonergic neurons

Figure 4: 8MM, total prevalence of MDD (%), men and women, ages ≥18 years, 2019

Figure 5: 8MM, sources used and not used to forecast the 12-month total prevalent cases of MDD

Figure 6: 8MM, sources used to forecast the 12-month total prevalent cases of MDD, by severity

Figure 7: 8MM, 12-month total prevalent cases of MDD, both sexes, ages ≥18 years, 2019

Figure 8: 8MM 12-month total prevalent cases of MDD, by age, N, both sexes, 2019

Figure 9: 8MM, 12-month total prevalent cases of MDD, by sex, N, ages ≥18 years, 2019

Figure 10: 8MM, total prevalent cases of MDD by severity, N, both sexes, ages ≥18 years, 2019

Figure 11: Disease management model for MDD

Figure 12: MDD treatment algorithm

Figure 13: Unmet needs and opportunities in MDD

Figure 14: Overview of the development pipeline in MDD

Figure 15: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for MDD in the 8MM during the forecast period

Figure 16: Competitive assessment of the pipeline drug monotherapies benchmarked against SOC Lexapro (escitalopram)

Figure 17: Competitive assessment of the pipeline adjunctive therapies benchmarked against the SOC, Abilify

Figure 18: Analysis of the company portfolio gap in MDD during the forecast period

Figure 19: Global (8MM) sales forecast by country for MDD in 2019 and 2029

Figure 20: Global (8MM) sales forecast by class for MDD in 2019 and 2029

Figure 21: Sales forecast by class for MDD in the US in 2019 and 2029

Figure 22: Sales forecast by country for MDD in the 5EU in 2019 and 2029

Figure 23: Sales forecast by class for MDD in the 5EU in 20219 and 2029

Figure 24: Sales forecast by class for MDD in Japan in 2019 and 2029

Figure 25: Sales forecast by class for MDD in Canada in 2019 and 2029